West Pharmaceutical Services, Inc. (WST) 10-Year Financial Performance & Capital Metrics

WST • • Industrial / General

HealthcareMedical InstrumentsMedical Consumables & DisposablesMedical Packaging & Containers

AboutWest Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.Show more

Revenue $2.89B -2.0%
EBITDA $750M -11.6%
Net Income $493M -17.0%
EPS (Diluted) 6.69 -15.1%
Gross Margin 34.65% -9.7%
EBITDA Margin 25.93% -9.8%
Operating Margin 20.56% -14.7%
Net Margin 17.03% -15.3%
ROE 17.71% -16.9%
ROIC 18.43% -23.2%
Debt/Equity 0.11 +6.1%
Interest Coverage 205.03 +153.8%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Excellent 3Y average ROE of 20.8%
✓Strong 5Y profit CAGR of 15.3%
✓24 consecutive years of dividend growth
✓High quality earnings: Operating CF exceeds net income
✓Share count reduced 2.1% through buybacks
✓Healthy 5Y average net margin of 19.4%

✗Weaknesses

No significant weaknesses identified

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y7.36%

5Y9.43%

3Y0.72%

TTM4.9%

Profit (Net Income) CAGR

10Y14.51%

5Y15.31%

3Y-9.37%

TTM-1.58%

EPS CAGR

10Y14.35%

5Y15.82%

3Y-8.28%

TTM0.15%

ROCE

10Y Avg19.25%

5Y Avg23.56%

3Y Avg22.67%

Latest19.03%

Peer Comparison

Medical Packaging & Containers

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
STVNStevanato Group S.p.A.	1.04B	21.00	48.84	1.72%	12.01%	9.78%		0.31
WSTWest Pharmaceutical Services, Inc.	20.1B	279.41	41.77	-1.98%	16.3%	16.11%	1.38%	0.11
ATRAptarGroup, Inc.	8.21B	125.11	22.62	2.74%	11.45%	14.91%	4.25%	0.43
MHUAMeihua International Medical Technologies Co., Ltd.	181.69M	3.25	0.08	-0.19%	10.09%	11.25%	7.98%	0.05

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	1.4B	1.51B	1.6B	1.72B	1.84B	2.15B	2.83B	2.89B	2.95B	2.89B
Revenue Growth %	-0.02%	0.08%	0.06%	0.07%	0.07%	0.16%	0.32%	0.02%	0.02%	-0.02%
Cost of Goods Sold+	943.9M	1.01B	1.09B	1.17B	1.23B	1.38B	1.66B	1.75B	1.82B	1.89B
COGS % of Revenue	0.68%	0.67%	0.68%	0.68%	0.67%	0.64%	0.59%	0.61%	0.62%	0.65%
Gross Profit+	454.1M	501M	514.8M	546.3M	608.8M	767.9M	1.17B	1.14B	1.13B	1B
Gross Margin %	0.32%	0.33%	0.32%	0.32%	0.33%	0.36%	0.41%	0.39%	0.38%	0.35%
Gross Profit Growth %	0.01%	0.1%	0.03%	0.06%	0.11%	0.26%	0.53%	-0.03%	-0.01%	-0.12%
Operating Expenses+	328.4M	285.5M	285.1M	291.5M	311.6M	348.9M	414.7M	375.4M	421.8M	407.6M
OpEx % of Revenue	0.23%	0.19%	0.18%	0.17%	0.17%	0.16%	0.15%	0.13%	0.14%	0.14%
Selling, General & Admin	233M	239.8M	246M	262.9M	272.7M	302M	361.9M	316.9M	353.4M	338.5M
SG&A % of Revenue	0.17%	0.16%	0.15%	0.15%	0.15%	0.14%	0.13%	0.11%	0.12%	0.12%
Research & Development	34.1M	36.8M	39.1M	40.3M	38.9M	46.9M	52.8M	58.5M	68.4M	69.1M
R&D % of Revenue	0.02%	0.02%	0.02%	0.02%	0.02%	0.02%	0.02%	0.02%	0.02%	0.02%
Other Operating Expenses	61.3M	8.9M	0	-11.7M	0	0	0	0	0	0
Operating Income+	125.7M	215.5M	229.7M	254.8M	297.2M	419M	758.7M	763.5M	710.9M	594.6M
Operating Margin %	0.09%	0.14%	0.14%	0.15%	0.16%	0.2%	0.27%	0.26%	0.24%	0.21%
Operating Income Growth %	-0.31%	0.71%	0.07%	0.11%	0.17%	0.41%	0.81%	0.01%	-0.07%	-0.16%
EBITDA+	215.6M	306.2M	326.4M	359.2M	400.6M	528.1M	881M	884.1M	848.2M	750M
EBITDA Margin %	0.15%	0.2%	0.2%	0.21%	0.22%	0.25%	0.31%	0.31%	0.29%	0.26%
EBITDA Growth %	-0.21%	0.42%	0.07%	0.1%	0.12%	0.32%	0.67%	0%	-0.04%	-0.12%
D&A (Non-Cash Add-back)	89.9M	90.7M	96.7M	104.4M	103.4M	109.1M	122.3M	120.6M	137.3M	155.4M
EBIT	127.8M	196.2M	229.5M	248.8M	299.8M	409.8M	757.4M	687.5M	706.8M	588.4M
Net Interest Income+	-10.1M	-5.3M	-5.8M	-6M	-4.2M	-7.1M	-7.5M	-2.5M	19.2M	16.7M
Interest Income	1.6M	1.1M	1.3M	2.1M	3.8M	1.4M	1M	5.1M	28M	19.6M
Interest Expense	11.7M	6.4M	7.1M	8.1M	8M	8.5M	8.5M	7.6M	8.8M	2.9M
Other Income/Expense	-3.8M	-17.5M	1.9M	-6.5M	3.5M	-300K	10.3M	-62.9M	4.8M	5.6M
Pretax Income+	121.9M	198M	231.6M	248.3M	300.7M	418.7M	769M	700.6M	715.7M	600.2M
Pretax Margin %	0.09%	0.13%	0.14%	0.14%	0.16%	0.2%	0.27%	0.24%	0.24%	0.21%
Income Tax+	26.3M	54.4M	80.9M	41.4M	59M	72.5M	107.2M	114.7M	122.3M	107.5M
Effective Tax Rate %	0.78%	0.73%	0.65%	0.83%	0.8%	0.83%	0.86%	0.84%	0.83%	0.82%
Net Income+	95.6M	143.6M	150.7M	206.9M	241.7M	346.2M	661.8M	585.9M	593.4M	492.7M
Net Margin %	0.07%	0.1%	0.09%	0.12%	0.13%	0.16%	0.23%	0.2%	0.2%	0.17%
Net Income Growth %	-0.25%	0.5%	0.05%	0.37%	0.17%	0.43%	0.91%	-0.11%	0.01%	-0.17%
Net Income (Continuing)	95.6M	143.6M	150.7M	206.9M	241.7M	346.2M	661.8M	585.9M	593.4M	492.7M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	1.30	1.91	1.99	2.74	3.21	4.57	8.67	7.73	7.88	6.69
EPS Growth %	-0.26%	0.47%	0.04%	0.38%	0.17%	0.42%	0.9%	-0.11%	0.02%	-0.15%
EPS (Basic)	1.33	1.96	2.04	2.80	3.27	4.68	8.90	7.88	7.99	6.75
Diluted Shares Outstanding	73.8M	75M	75.8M	75.4M	75.4M	75.8M	76.3M	75.8M	75.3M	73.7M
Basic Shares Outstanding	72M	73.3M	73.9M	73.9M	74M	73.9M	74.4M	74.4M	74.3M	73M
Dividend Payout Ratio	0.34%	0.25%	0.26%	0.2%	0.19%	0.14%	0.08%	0.09%	0.1%	0.12%

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	673.7M	641.9M	743.5M	894.4M	1.06B	1.37B	1.74B	1.92B	1.94B	1.54B
Cash & Short-Term Investments	274.6M	203M	235.9M	337.4M	439.1M	615.5M	762.6M	894.3M	853.9M	484.6M
Cash Only	274.6M	203M	235.9M	337.4M	439.1M	615.5M	762.6M	894.3M	853.9M	484.6M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	181.4M	200.5M	253.2M	288.2M	319.3M	385.3M	489M	507.4M	512M	552.5M
Days Sales Outstanding	47.36	48.49	57.75	61.23	63.22	65.51	63.05	64.18	63.33	69.71
Inventory	181.1M	199.3M	215.2M	214.5M	235.7M	321.3M	378.4M	414.8M	434.7M	377M
Days Inventory Outstanding	70.03	72.16	72.37	66.82	69.67	85.06	83.34	86.68	87.26	72.79
Other Current Assets	36.6M	39.1M	39.2M	54.3M	64.6M	51.6M	112M	103M	135.8M	124M
Total Non-Current Assets+	1.02B	1.07B	1.12B	1.08B	1.28B	1.42B	1.57B	1.7B	1.89B	2.11B
Property, Plant & Equipment	721M	778.3M	855M	822M	909.4M	1.01B	1.13B	1.26B	1.51B	1.69B
Fixed Asset Turnover	1.94x	1.94x	1.87x	2.09x	2.03x	2.12x	2.51x	2.29x	1.95x	1.72x
Goodwill	104.6M	103M	107.7M	105.8M	107.8M	111.1M	109.9M	107.3M	108.5M	106.1M
Intangible Assets	37.6M	23.3M	21.7M	20.4M	29.8M	30.5M	23M	18.4M	15.1M	10.8M
Long-Term Investments	61.3M	82.7M	85.8M	91.2M	192.7M	214.7M	207.7M	204.9M	210M	202.1M
Other Non-Current Assets	26.4M	21.3M	23.4M	20.5M	29M	36.3M	55.9M	38.4M	21.3M	74.3M
Total Assets+	1.7B	1.72B	1.86B	1.59B	2.34B	2.79B	3.31B	3.62B	3.83B	3.64B
Asset Turnover	0.82x	0.88x	0.86x	1.08x	0.79x	0.77x	0.85x	0.80x	0.77x	0.79x
Asset Growth %	0.01%	0.01%	0.09%	-0.15%	0.47%	0.19%	0.19%	0.09%	0.06%	-0.05%
Total Current Liabilities+	314.3M	241M	279.5M	283.7M	341.6M	503.4M	594.1M	519M	671.8M	550.4M
Accounts Payable	119.8M	122M	138.1M	130.4M	156.8M	213.1M	232.2M	215.4M	242.4M	239.3M
Days Payables Outstanding	46.33	44.17	46.44	40.62	46.35	56.41	51.14	45.01	48.66	46.2
Short-Term Debt	69.3M	2.4M	0	100K	2.3M	2.3M	44.2M	2.2M	134M	18.8M
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	13.3M	17.5M	22.7M	22.6M	28.8M	49.9M	45.1M	54M	54.2M	100.5M
Current Ratio	2.14x	2.66x	2.66x	3.15x	3.10x	2.73x	2.93x	3.70x	2.88x	2.79x
Quick Ratio	1.57x	1.84x	1.89x	2.40x	2.41x	2.09x	2.30x	2.90x	2.24x	2.11x
Cash Conversion Cycle	71.07	76.48	83.68	87.43	86.54	94.16	95.25	105.85	101.93	96.3
Total Non-Current Liabilities+	356.9M	358.2M	303.4M	298.9M	426.6M	435.9M	384.3M	412.9M	276.7M	410.7M
Long-Term Debt	228.9M	226.2M	197M	196M	255M	252.9M	208.8M	206.7M	72.8M	202.6M
Capital Lease Obligations	0	0	0	0	62.4M	60.4M	63M	93M	84.5M	83.9M
Deferred Tax Liabilities	12.4M	9.2M	10.4M	13.1M	15.5M	10.4M	4.9M	14.3M	12.7M	20.5M
Other Non-Current Liabilities	115.6M	122.8M	96M	89.8M	93.7M	112.2M	107.6M	98.9M	106.7M	103.7M
Total Liabilities	671.2M	599.2M	582.9M	582.6M	768.2M	939.3M	978.4M	931.9M	948.5M	961.1M
Total Debt+	298.2M	228.6M	197M	196.1M	329.3M	325.7M	325.3M	317.9M	309M	305.3M
Net Debt	23.6M	25.6M	-38.9M	-141.3M	-109.8M	-289.8M	-437.3M	-576.4M	-544.9M	-179.3M
Debt / Equity	0.29x	0.20x	0.15x	0.14x	0.21x	0.18x	0.14x	0.12x	0.11x	0.11x
Debt / EBITDA	1.38x	0.75x	0.60x	0.55x	0.82x	0.62x	0.37x	0.36x	0.36x	0.41x
Net Debt / EBITDA	0.11x	0.08x	-0.12x	-0.39x	-0.27x	-0.55x	-0.50x	-0.65x	-0.64x	-0.24x
Interest Coverage	10.74x	33.67x	32.35x	31.46x	37.15x	49.29x	89.26x	100.46x	80.78x	205.03x
Total Equity+	1.02B	1.12B	1.28B	1.4B	1.57B	1.85B	2.34B	2.68B	2.88B	2.68B
Equity Growth %	0.07%	0.09%	0.15%	0.09%	0.13%	0.18%	0.26%	0.15%	0.07%	-0.07%
Book Value per Share	13.87	14.90	16.89	18.52	20.86	24.47	30.61	35.42	38.26	36.39
Total Shareholders' Equity	1.02B	1.12B	1.28B	1.4B	1.57B	1.85B	2.34B	2.68B	2.88B	2.68B
Common Stock	18.1M	18.4M	18.8M	18.8M	18.8M	18.8M	18.8M	18.8M	18.8M	18.8M
Retained Earnings	964.6M	1.07B	1.18B	1.35B	1.55B	1.85B	2.46B	2.99B	3.52B	3.96B
Treasury Stock	-4M	-46.1M	-109.1M	-103.7M	-118.1M	-167.7M	-229.5M	-370.9M	-637.6M	-1.06B
Accumulated OCI	-162.6M	-186.8M	-117.3M	-154.2M	-149.6M	-110.6M	-159.6M	-183M	-143.8M	-258.1M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	212.4M	219.4M	263.3M	288.6M	367.2M	472.5M	584M	724M	776.5M	653.4M
Operating CF Margin %	0.15%	0.15%	0.16%	0.17%	0.2%	0.22%	0.21%	0.25%	0.26%	0.23%
Operating CF Growth %	0.16%	0.03%	0.2%	0.1%	0.27%	0.29%	0.24%	0.24%	0.07%	-0.16%
Net Income	95.6M	143.6M	150.7M	206.9M	241.7M	346.2M	661.8M	585.9M	593.4M	492.7M
Depreciation & Amortization	89.9M	90.7M	96.7M	104.4M	103.4M	109.1M	122.3M	120.6M	137.3M	155.4M
Stock-Based Compensation	29.6M	19.5M	16.1M	15.1M	24.4M	34M	37.5M	23.7M	23.3M	18.7M
Deferred Taxes	-8.9M	21.5M	41.7M	900K	15.3M	-5.8M	-42.9M	-30.8M	37.5M	0
Other Non-Cash Items	17M	2.8M	-500K	-10.4M	-3.2M	-700K	-900K	36.1M	5.4M	-16.3M
Working Capital Changes	-10.8M	-58.7M	-41.4M	-28.3M	-14.4M	-10.3M	-193.8M	-15M	-20.4M	2.9M
Change in Receivables	-14.1M	-23.3M	-39.7M	-43.8M	-33.3M	-46.6M	-123.5M	-35.6M	4M	-58.8M
Change in Inventory	-11.4M	-21.2M	-3.6M	-7M	-18.6M	-73.7M	-86.5M	-49.8M	-13.5M	42M
Change in Payables	17.2M	6.1M	12.6M	400K	25.3M	36.6M	16.8M	-2.8M	4.4M	2.9M
Cash from Investing+	-129.5M	-175.8M	-133.6M	-100.8M	-228M	-179.5M	-253.1M	-288.2M	-368.7M	-378.7M
Capital Expenditures	-131.6M	-170.2M	-130.8M	-104.7M	-126.4M	-174.4M	-253.4M	-284.6M	-362M	-377M
CapEx % of Revenue	0.09%	0.11%	0.08%	0.06%	0.07%	0.08%	0.09%	0.1%	0.12%	0.13%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	2.1M	2.8M	3.2M	3.9M	2.4M	-5.1M	2.5M	-3.6M	-6.7M	-1.7M
Cash from Financing+	-41.5M	-113.9M	-109M	-80.7M	-36.8M	-137.1M	-168.1M	-293.6M	-459.6M	-622.6M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-32.4M	-35.8M	-39.1M	-42.1M	-45.1M	-48.1M	-51.1M	-54.1M	-57M	-59.1M
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	23.9M	47.6M	39.4M	32.3M	31.5M	34.7M	37.1M	27M	50.9M	30.7M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	80.8M	49.2M	132.5M	183.9M	240.8M	298.1M	330.6M	439.4M	414.5M	276.4M
FCF Margin %	0.06%	0.03%	0.08%	0.11%	0.13%	0.14%	0.12%	0.15%	0.14%	0.1%
FCF Growth %	0.14%	-0.39%	1.69%	0.39%	0.31%	0.24%	0.11%	0.33%	-0.06%	-0.33%
FCF per Share	1.09	0.66	1.75	2.44	3.19	3.93	4.33	5.80	5.50	3.75
FCF Conversion (FCF/Net Income)	2.22x	1.53x	1.75x	1.39x	1.52x	1.36x	0.88x	1.24x	1.31x	1.33x
Interest Paid	14.7M	8.6M	8M	8.4M	8.6M	8.1M	8M	6.6M	6M	500K
Taxes Paid	33.1M	48.1M	31M	42M	47.5M	48.4M	171.8M	109.7M	90.8M	71.4M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	9.65%	13.41%	12.57%	15.46%	16.28%	20.2%	31.59%	23.34%	21.32%	17.71%
Return on Invested Capital (ROIC)	9.04%	14.76%	14.45%	15.31%	16.4%	20.76%	32.87%	28.58%	23.99%	18.43%
Gross Margin	32.48%	33.2%	32.17%	31.8%	33.02%	35.77%	41.45%	39.47%	38.38%	34.65%
Net Margin	6.84%	9.52%	9.42%	12.04%	13.11%	16.13%	23.38%	20.3%	20.11%	17.03%
Debt / Equity	0.29x	0.20x	0.15x	0.14x	0.21x	0.18x	0.14x	0.12x	0.11x	0.11x
Interest Coverage	10.74x	33.67x	32.35x	31.46x	37.15x	49.29x	89.26x	100.46x	80.78x	205.03x
FCF Conversion	2.22x	1.53x	1.75x	1.39x	1.52x	1.36x	0.88x	1.24x	1.31x	1.33x
Revenue Growth	-1.67%	7.95%	6.04%	7.36%	7.31%	16.44%	31.86%	1.94%	2.27%	-1.98%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Proprietary Products	-	-	-	-	-	-	2.32B	2.41B	2.4B	2.33B
Proprietary Products Growth	-	-	-	-	-	-	-	3.86%	-0.39%	-2.62%
Contract Manufactured Products	-	320.2M	362.5M	409.1M	441.5M	498.6M	514.7M	480.4M	552.5M	558.7M
Contract Manufactured Products Growth	-	-	13.21%	12.86%	7.92%	12.93%	3.23%	-6.66%	15.01%	1.12%
Packaging Systems	1B	-	-	-	-	-	-	-	-	-
Packaging Systems Growth	-	-	-	-	-	-	-	-	-	-
Delivery Systems	400.2M	-	-	-	-	-	-	-	-	-
Delivery Systems Growth	-	-	-	-	-	-	-	-	-	-

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
UNITED STATES	667.4M	738.3M	734.6M	766.1M	814.7M	975.6M	1.2B	1.29B	1.24B	1.23B
UNITED STATES Growth	-	10.62%	-0.50%	4.29%	6.34%	19.75%	22.80%	7.39%	-3.73%	-0.62%
Other Europe Countries	252M	268.3M	318.5M	386.1M	251.1M	236.8M	341.3M	359.2M	388.1M	385.5M
Other Europe Countries Growth	-	6.47%	18.71%	21.22%	-34.97%	-5.69%	44.13%	5.24%	8.05%	-0.67%
GERMANY	194M	200.6M	226.4M	235.9M	236.3M	282.1M	474.3M	398.7M	406.1M	372.5M
GERMANY Growth	-	3.40%	12.86%	4.20%	0.17%	19.38%	68.13%	-15.94%	1.86%	-8.27%
Other Countries	178.8M	185.6M	194M	201.8M	213.4M	253.7M	357.4M	364.3M	348.5M	339M
Other Countries Growth	-	3.80%	4.53%	4.02%	5.75%	18.88%	40.88%	1.93%	-4.34%	-2.73%
IRELAND	-	-	-	-	173.8M	226M	247.6M	240.3M	285.7M	323.2M
IRELAND Growth	-	-	-	-	-	30.03%	9.56%	-2.95%	18.89%	13.13%
FRANCE	107.6M	116.3M	125.6M	127.5M	150.6M	172.7M	213M	237.9M	282.9M	242.2M
FRANCE Growth	-	8.09%	8.00%	1.51%	18.12%	14.67%	23.34%	11.69%	18.92%	-14.39%

Frequently Asked Questions

Valuation & Price

West Pharmaceutical Services, Inc. (WST) has a price-to-earnings (P/E) ratio of 41.8x. This suggests investors expect higher future growth.

Growth & Financials

West Pharmaceutical Services, Inc. (WST) reported $3.02B in revenue for fiscal year 2024. This represents a 153% increase from $1.19B in 2011.

West Pharmaceutical Services, Inc. (WST) saw revenue decline by 2.0% over the past year.

Yes, West Pharmaceutical Services, Inc. (WST) is profitable, generating $491.7M in net income for fiscal year 2024 (17.0% net margin).

Dividend & Returns

Yes, West Pharmaceutical Services, Inc. (WST) pays a dividend with a yield of 0.29%. This makes it attractive for income-focused investors.

West Pharmaceutical Services, Inc. (WST) has a return on equity (ROE) of 17.7%. This is reasonable for most industries.

West Pharmaceutical Services, Inc. (WST) generated $379.1M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...